Category: ESMO

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

September 15, 2024

•

Investor Empires

Article Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…
Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

September 15, 2024

•

Investor Empires

Article Content Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one FDA-approved drug and 30 in development. Quantitative PSMA-PET imaging is required to determine patient eligibility for the first FDA-approved PSMA-targeted drug and is an inclusion criterion for ongoing trials. BOSTON, Sept. 15, 2024…
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

September 14, 2024

•

Investor Empires

Updated Phase 1 dose-escalation data from ARROS-1 and ALKOVE-1 clinical trials continue to support potential best-in-class profiles for zidesamtinib and NVL-655 Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase…
™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com

July 17, 2024

•

Investor Empires

Berlin-(Business):™E Pharma NV (Euronext Growth Paris: AL™E), A clinical-stage biotechnology company focused on developing novel therapies to treat cancer by targeting the tumor environ- ment (E™), today announced that an abstract including results from the NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) has been selected for presentation…

Category: ESMO

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

™E Pharma Announces Oral Presentation of NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma at ESMO Congress 2024 By Investing.com